Discussion posted by: Arye ben-Shaoul
RedHill Biopharma has reported preliminary data from a compassionate use programme of opaganib (Yeliva, ABC294640) to treat Covid-19 patients in Israel. The results are from two patients who had moderate to severe Covid-19-related acute respiratory symptoms. These patients needed supplemental oxygenation and experienced hypoxia even after treatment with maximum oxygen flow using cannulas. The patients were given opaganib plus standard-of-care, including hydroxychloroquine (HCQ) as background therapy. Opaganib is an investigational sphingosine kinase-2 (SK2) selective inhibitor said to possess anticancer, anti-viral and anti-inflammatory properties. According to the data, both patients showed clinical improvement within days after treatment-initiation with opaganib.